Therapy News and Research

RSS

Maternal posttraumatic stress, depression and anxiety common after prenatal diagnosis of CHD

Heart defects are the most common form of congenital malformations affecting newborns. Infants who were prenatally diagnosed with congenital heart disease (CHD) are more stable and have better outcomes than infants who were diagnosed after birth. Diagnosing CHD in a fetus also allows mothers to educate themselves on heart malformations, consider their options, and potentially plan for intervention or surgery after birth.

7 Sep 2012

PCI after lung cancer treatment reduces risk of brain metastases in stage III NSCLC patients

Stage III non-small cell lung cancer (NSCLC) patients treated with surgery and/or radiation therapy have a significantly reduced risk of developing brain metastases if they also receive prophylactic cranial irradiation (PCI); however, this study did not show an improvement in overall survival with PCI, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

RSV virus selectively kills cancer cells

RSV, a virus that causes respiratory infections in infants and young children, selectively kills cancer cells while leaving healthy cells alone, researchers from the School of Medicine at The University of Texas Health Science Center San Antonio said.

7 Sep 2012

Longer looks: Insurers balk at price of new asthma relief; Despite health law, costs still overwhelming for some patients

For two decades, Patricia DiGiusto struggled with severe asthma. Powerful medications and frequent use of her inhaler could not prevent repeated trips to the emergency room. ... Two years ago, Ms. DiGiusto's doctor told her about a new procedure called bronchial thermoplasty, the first non-drug therapy approved by the Food and Drug Administration for patients with severe asthma.

7 Sep 2012

Durata completes target enrollment in dalbavancin Phase 3 trials for abSSSI

Durata Therapeutics today announced that it has completed its target enrollment for DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response"), one of two ongoing, global, Phase 3 clinical trials of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (abSSSI).

7 Sep 2012

Vitamin D supplements have unintended lipid consequences

Correcting vitamin D levels in individuals at risk for cardiovascular disease may have detrimental effects on their lipid profiles, report researchers.

6 Sep 2012

WOEST: Dual antiplatelet therapy more effective than triple

Dual antiplatelet therapy with clopidogrel and an oral anticoagulant reduces bleeding and mortality more effectively than triple therapy including aspirin, researchers say.

6 Sep 2012

A significant proportion of breast cancer survivors have chronic fatigue

UK study results show that over a third of breast cancer survivors have cancer-related fatigue syndrome and that these women have significantly lower subjective quality of life and mood than their nonfatigued peers.

6 Sep 2012

Preliminary research findings from Kessler Foundation’s Ekso device study on SCI

Kessler Foundation has released preliminary research findings from its clinical study of the wearable robotic exoskeletal device, Ekso. Gail Forrest, PhD, assistant director of Human Performance and Engineering Research, presented the Ekso research data on September 3, at the meeting of the Academy of Spinal Cord Injury Professionals at the Rio Suites in Las Vegas. Dr. Forrest directs mobility research at the Foundation, including activity-based locomotor therapy, functional electrical stimulation, and treadmill training with the LokomatPro v6, as well as Ekso.

6 Sep 2012

Injecting capsule with heat-generating cells reduces abdominal and belly fat in mice

The injection of a tiny capsule containing heat-generating cells into the abdomens of mice led those animals to burn abdominal fat and initially lose about 20 percent of belly fat after 80 days of treatment.

6 Sep 2012

Study sheds light on why women gain fat following menopause

A high-fat diet triggers chemical reactions in female mice that could explain why women are more likely than men to gain fat in the abdomen after eating excess saturated fat, new research suggests. The study also sheds light on why women gain fat following menopause.

6 Sep 2012

Expenditures for treatment of back and neck problems have nearly doubled since late 1990s

Expenditures for treatment of back and neck problems have nearly doubled since the late 1990s—mainly from increased spending for care provided by medical specialists, according to a report in the September 1 issue of Spine.

6 Sep 2012

Clinical trial to test combination of two drugs in treating fibromyalgia

A chronic pain condition and numerous gastrointestinal disorders may all be caused by a virus. That's a Tuscaloosa-based surgeon's theory likely headed for a clinical trial early next year and one drawing support from a University of Alabama researcher who studies how viruses replicate.

6 Sep 2012

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

The drug telaprevir has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether telaprevir offers an added benefit compared with the present standard therapy.

6 Sep 2012

Scripps Florida designs new compound that shows promise against tremor ataxia syndrome

Scientists on the Florida campus of The Scripps Research Institute have designed a compound that shows promise as a potential therapy for one of the diseases closely linked to fragile X syndrome, a genetic condition that causes mental retardation, infertility, and memory impairment, and is the only known single-gene cause of autism.

6 Sep 2012

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG Pharmaceuticals, Inc. today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

6 Sep 2012

FDA continues review of Salix’s Crofelemer new drug application

Napo Pharmaceuticals, Inc. was informed today that the Food and Drug Administration is continuing its review of the new drug application seeking approval of crofelemer for the treatment of chronic diarrhea in people living with HIV/AIDS on anti-retroviral therapy.

6 Sep 2012

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.

6 Sep 2012

Therapy News and Research

Maternal posttraumatic stress, depression and anxiety common after prenatal diagnosis of CHD

PCI after lung cancer treatment reduces risk of brain metastases in stage III NSCLC patients

RSV virus selectively kills cancer cells

Longer looks: Insurers balk at price of new asthma relief; Despite health law, costs still overwhelming for some patients

Durata completes target enrollment in dalbavancin Phase 3 trials for abSSSI

Vitamin D supplements have unintended lipid consequences

WOEST: Dual antiplatelet therapy more effective than triple

A significant proportion of breast cancer survivors have chronic fatigue

Preliminary research findings from Kessler Foundation’s Ekso device study on SCI

Injecting capsule with heat-generating cells reduces abdominal and belly fat in mice

Study sheds light on why women gain fat following menopause

Expenditures for treatment of back and neck problems have nearly doubled since late 1990s

Clinical trial to test combination of two drugs in treating fibromyalgia

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

Scripps Florida designs new compound that shows promise against tremor ataxia syndrome

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

FDA continues review of Salix’s Crofelemer new drug application

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News